Immunotherapeutic approaches in multiple sclerosis

Journal of the Neurological Sciences

Volumn 223, Issue 1, 2004, Pages 13-24

  Adorini, Luciano ^a  

^a BioXell SpA   (Italy)

Author keywords

Chemokines; Cytokines; Dendritic cells; Regulatory T cells; Th1 Th1 cells

Indexed keywords

ALEMTUZUMAB; ANTIGEN; ANTIINFLAMMATORY AGENT; AUTOANTIGEN; BETA INTERFERON; BETA1A INTERFERON; CD40 LIGAND MONOCLONAL ANTIBODY; COLLAGEN TYPE 2; CYTOKINE; DNA VACCINE; ETANERCEPT; GAMMA INTERFERON; GLATIRAMER; IMMUNOGLOBULIN ANTIBODY; INFLIXIMAB; INTERFERON BETA SERINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 12 RECEPTOR ANTAGONIST; INTERLEUKIN 4; INTERLEUKIN 4 ANTIBODY; LENERCEPT; MYELIN; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN [87-99]; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PEPTIDE DERIVATIVE; RECEPTOR BLOCKING AGENT; RETINA S ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; ENCEPHALITIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TREATMENT FAILURE; TREATMENT OUTCOME; UVEITIS; VACCINATION;

EID: 3142628216     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2004.04.014     Document Type: Article

References (130)

1. Adorini L. Selective immunointervention in autoimmune diseases: lessons from multiple sclerosis. J. Chemother. 13:2001;219
2. Wiendl H., Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs. 16:2002;183
3. Harrison L.C., Hafler D.A. Antigen-specific therapy for autoimmune disease. Curr. Opin. Immunol. 12:2000;704
4. Garcia G., Weiner H.L. Manipulation of Th responses by oral tolerance. Curr. Top. Microbiol. Immunol. 238:1999;123
5. Weiner H.L., Mackin G.A., Matsui M., Orav E.J., Khoury S.J., Dawson D.M., et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 259:1993;1321
6. Barnett M.L., Kremer J.M., St. Clair E.W., Clegg D.O., Furst D., Weisman M., et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial [published erratum appears in Arthritis Rheum. 1998 May; 41 (5): 938] [see comments]. Arthritis Rheum. 41:1998;290
7. Nussenblatt R.B., Gery I., Weiner H.L., Ferris F.L., Shiloach J., Remaley N., et al. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial [see comments]. Am. J. Ophthalmol. 123:1997;583
8. Evavold B.D., Sloan-Lancaster J., Allen P.M. Tickling the TCR: selective T cell functions stimulated by altered peptide ligands. Immunol. Today. 14:1993;602
9. Racioppi L., Germain R.N. Modified T-cell receptor ligands: moving beyond a strict occupancy model for T-cell activation by antigen. Chem. Immunol. 60:1995;79
10. Sette A., Alexander J., Snoke K., Grey H.M. Antigen analogs as tools to study T-cell activation function and activation. Semin. Immunol. 8:1996;103
11. Anderton S.M., Kissler S., Lamont A.G., Wraith D.C. Therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells. Eur. J. Immunol. 29:1999;1850
12. Ruiz P.J., Garren H., Hirschberg D.L., Langer-Gould A.M., Levite M., Karpuj M.V., et al. Microbial epitopes act as altered peptide ligands to prevent experimental autoimmune encephalomyelitis. J. Exp. Med. 189:1999;1275
13. Brocke S., Gijbels K., Allegretta M., Ferber I., Piercy C., Blankenstein T., et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 379:1996;343
14. Nicholson L.B., Greer J.M., Sobel R.A., Lees M.B., Kuchroo V.K. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity. 3:1995;397
15. Windhagen A., Scholz C., Hollsberg P., Fukaura H., Sette A., Hafler D.A. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity. 2:1995;373
16. Kappos L., Comi G., Panitch H., Oger J., Antel J., Conlon P., et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat. Med. 6:2000;1176
17. Steinman L., Conlon P. Antigen specific immunotherapy of multiple sclerosis. J. Clin. Immunol. 21:2001;93
18. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6:2000;1167
19. Aharoni R., Teitelbaum D., Arnon R., Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc. Natl. Acad. Sci. U. S. A. 96:1999;634
20. Lenardo M., Chan K., Hornung F., McFarland H., Siegel R., Wang J., et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 17:1999;221
21. Siegel R.M., Fleisher T.A. The role of Fas and related death receptors in autoimmune and other disease states. J. Allergy Clin. Immunol. 103:1999;729
22. Zang Y.C., Kozovska M.M., Hong J., Li S., Mann S., Killian J.M., et al. Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur. J. Immunol. 29:1999;1692
23. Racke M.K., Critchfield J.M., Quigley L., Cannella B., Raine C.S., McFarland H.F. Intravenous antigen administration as a therapy for autoimmune demyelinating disease. Ann. Neurol. 93:1996;46
24. Ishigami T., White C., Pender M. Soluble antigen therapy induces apoptosis of autoreactive T cells preferentially in the target organ rather than in the peripheral lymphoid organs. Eur. J. Immunol. 28:1998;1623
25. Chen Y., Inobe J.-I., Marks R., Gonnella P., Kuchroo V.K., Weiner H.L. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature. 376:1995;177
26. Elliott E., McFarland H., Nye S., Cofiell R., Wilson T., Wilkins J., et al. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. J. Clin. Invest. 87:1996;1602
27. McFarland H., Lobito A., Johnson M., Nyswaner J., Frank J., Palardy G., et al. Determinant spreading associated with demyelination in a nonhuman primate model of multiple sclerosis. J. Immunol. 162:1999;2384
28. Lehmann P., Sercarz E., Forsthuber T., Dayan C., Gammon G. Determinant spreading and the dynamics of the autoimmune T cell repertoire. Immunol. Today. 14:1993;203
29. Coles A.J., Wing M., Smith S., Coraddu F., Greer S., Taylor C., et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 354:1999;1691
30. Schwartz R.H. T cell anergy. Annu. Rev. Immunol. 21:2003;305
31. Salomon B., Bluestone J.A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19:2001;225
32. Grewal I., Flavell R. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16:1998;111
33. Matthews J.B., Ramos E., Bluestone J.A. Clinical trials of transplant tolerance: slow but steady progress. Am. J. Transplant. 3:2003;794
34. Bachmann M.F., Speiser D.E., Mak T.W., Ohashi P.S. Absence of co-stimulation and not the intensity of TCR signaling is critical for the induction of T cell unresponsiveness in vivo. Eur. J. Immunol. 29:1999;2156
35. Aloisi F., Penna G., Polazzi L., Minghetti L., Adorini L. CD40-CD154 interaction and IFN-g are required for IL-12 but not prostaglandin E2 secretion by microglia during antigen presentation to Th1 cells. J. Immunol. 162:1999;1384
36. Howard L.M., Miga A.J., Vanderlugt C.L., Dal Canto M.C., Laman J.D., Noelle R.J., et al. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J. Clin. Invest. 103:1999;281
37. Kawai T., Andrews D., Colvin R.B., Sachs D.H., Cosimi A.B. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand [In Process Citation]. Nat. Med. 6:2000;114
38. Karandikar N.J., Vanderlugt C.L., Walunas T.L., Miller S.D., Bluestone J.A. CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 184:1996;783
39. Ruiz P.J., Garren H., Ruiz I.U., Hirschberg D.L., Nguyen L.V., Karpuj M.V., et al. Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. J. Immunol. 162:1999;3336
40. Abrams J.R., Lebwohl M.G., Guzzo C.A., Jegasothy B.V., Goldfarb M.T., Goffe B.S., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103:1999;1243
41. Murphy K.M., Reiner S.L. The lineage decisions of helper T cells. Nat. Rev., Immunol. 2:2002;933
42. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity. 8:1998;275
43. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 13:2000;715
44. Brod S.A., Benjamin D., Hafler D.A. Restricted T cell expression of IL-2, IFN-g mRNA in human inflammatory disease. J. Immunol. 147:1991;810
45. Windhagen A., Newcombe J., Dangond F., Strand C., Woodroofe M.N., Cuzner M.L., et al. Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 182:1995;1985
46. +T cells via CD40 ligand. Proc. Natl. Acad. Sci. U. S. A. 94:1997;599
47. Comabella M., Balashov K., Issazadeh S., Smith D., Weiner H.L., Khoury S.J. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J. Clin. Invest. 102:1998;671
48. Segal B.M., Dwyer B.K., Shevach E.M. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med. 187:1998;537
49. Bettelli E., Prabhu Das M., Howard E.D., Weiner H.L., Sobel R.A., Kuchroo V.K. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10-and IL-4-deficient and transgenic mice. J. Immunol. 161:1998;3299
50. Lafaille J.J., Van-de-Keere F., Hsu A.L., Baron J.L., Haas W., Raine C.S. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from disease. J. Exp. Med. 186:1997;307
51. Genain C.P., Abel K., Belmar N., Villinger F., Rosenberg D.P., Linigton C., et al. Late complications of immune deviation therapy in a nonhuman primate. Science. 274:1996;2054
52. Acha-Orbea H., Mitchell D.J., Timmermann L., Wraith D.C., Tausch G.S., Waldor M.K., et al. Limited heterogeneity of T cell receptors in experimental allergic encephalomyelitis. Cell. 54:1988;263
53. Waisman A., Ruiz P.J., Hirschenberg D.L., Gelman A., Oskenberg J.R., Brocke S., et al. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat. Med. 2:1996;899
54. Lobell A., Weissert R., Eltayeb S., de Graaf K.L., Wefer J., Storch M.K., et al. Suppressive DNA vaccination in myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis involves a T1-biased immune response. J. Immunol. 170:2003;1806
55. Adorini L. Cytokine-based immunointervention in the treatment of autoimmune diseases. Clin. Exp. Immunol. 132:2003;185
56. Mathisen P.M., Tuohy V.K. Gene therapy in the treatment of autoimmune disease. Immunol. Today. 19:1998;103
57. Martino G., Furlan R., Galbiati F., Poliani P.L., Bergami A., Grimaldi L.M., et al. A gene therapy approach to treat demyelinating diseases using non-replicative herpetic vectors engineered to produce cytokines. Mult. Scler. 4:1998;222
58. Baker D., Hankey D.J. Gene therapy in autoimmune, demyelinating disease of the central nervous system. Gene Ther. 10:2003;844
59. Dinarello C.A. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int. Rev. Immunol. 16:1998;457
60. Furlan R., Martino G., Galbiati F., Poliani P.L., Smiroldo S., Bergami A., et al. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J. Immunol. 163:1999;2403
61. Panitch H.S., Hirsch R.L., Schindler J., Johnson K.P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 37:1987;1097
62. Krakowski M., Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 26:1996;1641
63. Furlan R., Brambilla E., Ruffini F., Poliani P.L., Bergami A., Marconi P.C., et al. Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J. Immunol. 167:2001;1821
64. Martino G., Adorini L., Rieckmann P., Hillert J., Kallmann B., Comi G., et al. Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol. 1:2002;499
65. Gately M.K., Renzetti L.M., Magram J., Stern A.S., Adorini L., Gubler U., et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16:1998;495
66. Aloisi F., Penna G., Cerase J., Menéndez Iglesias B., Adorini L. IL-12 production by central nervous system microglia is inhibited by astrocytes. J. Immunol. 159:1997;1604
67. Adorini L. Interleukin-12, a key cytokine in Th1-mediated autoimmune diseases. Cell. Mol. Life Sci. 55:1999;1610
68. Constantinescu C.S., Wysocka M., Hilliard B., Ventura E., Lavi E., Trinchieri G., et al. Antibodies against interleukin-12 prevent superantigen-induced and spontaneous relapses of experimental allergic encephalomyelitis. J. Immunol. 161:1998;5097
69. Ferrante P., Fusi M., Sarasella M., Caputo D., Biasin M., Trabattoni D., et al. Cytokine production and surface marker expression in acute and stable multiple sclerosis: altered IL-12 production augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis. J. Immunol. 160:1998;1514
70. Brok H.P., van Meurs M., Blezer E., Schantz A., Peritt D., Treacy G., et al. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J. Immunol. 169:2002;6554
71. Rogler G., Andus T. Cytokines in inflammatory bowel disease. World J. Surg. 22:1998;382
72. Adorini L. Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Int. Immunopharmacol. 2:2002;1017
73. Keating G.M., Perry C.M. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs. 16:2002;111
74. Culy C.R., Keating G.M. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs. 62:2002;2495
75. Mikuls T.R., Moreland L.W. Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Saf. 26:2003;23
76. Fleischmann R., Iqbal I., Nandeshwar P., Quiceno A. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf. 25:2002;173
77. Liu J., Marino M.W., Wong G., Grail D., Dunn A., Bettadapura J., et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med. 4:1998;78
78. van Oosten B.W., Barkhof F., Truyen L., Boringa J.B., Bertelsmann F.W., von Blomberg B.M., et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 47:1996;1531
79. Group, T.L.M.S.S.G.a.T.U.o.B.C.M.M.A. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology. 53:1999;457
80. Racke M.K., Bonomo A., Scott D.E., Cannella B., Levine A., Raine C.S., et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180:1994;1961
81. Ghoreschi K., Thomas P., Breit S., Dugas M., Mailhammer R., Van Eden W., et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9:2003;40
82. Furlan R., Poliani P.L., Galbiati F., Bergami A., Grimaldi L., Comi G., et al. Central nervous system delivery of interleukin 4 by a nonreplicative herpes simplex type 1 viral vector ameliorates autoimmune demyelination. Hum. Gene Ther. 9:1998;2605
83. Furlan R., Poliani P.L., Marconi P.C., Bergami A., Ruffini F., Adorini L., et al. Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice. Gene Ther. 8:2001;13
84. Poliani P.L., Brok H., Furlan R., Ruffini F., Bergami A., Desina G., et al. Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. Hum. Gene Ther. 12:2001;905
85. Martino G., Furlan R., Comi G., Adorini L. The ependymal route to the CNS: an emerging gene-therapy approach for MS. Trends Immunol. 22:2001;483
86. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:2001;683
87. +T cells. J. Exp. Med. 184:1996;19
88. Cua D.J., Hutchins B., LaFace D.M., Stohlman S.A., Coffman R.L. Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. J. Immunol. 166:2001;602
89. Martino G., Poliani P.L., Furlan R., Marconi P., Glorioso J.C., Adorini L., et al. Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach. J. Neuroimmunol. 107:2000;184
90. Panitch H.S., Hirsch R.L., Haley A.S., Johnson K.P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1:1987;893
91. Khan O., Zabad R., Caon C., Zvartau-Hind M., Tselis A., Lisak R. Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis. CNS Drugs. 16:2002;563
92. Arnason B.G. Immunologic therapy of multiple sclerosis. Annu. Rev. Med. 50:1999;291
93. Hohlfeld R., Wekerle H. Immunological update on multiple sclerosis. Curr. Opin. Neurol. 14:2001;299
94. Rep M.H., Schrijver H.M., van Lopik T., Hintzen R.Q., Roos M.T., Ader H.J., et al. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients. J. Neuroimmunol. 96:1999;92
95. Furlan R., Bergami A., Lang R., Brambilla E., Franciotta D., Martinelli V., et al. Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4. J. Neuroimmunol. 111:2000;86
96. Letterio J.J., Roberts A.B. Regulation of immune responses by TGF-beta. Annu. Rev. Immunol. 16:1998;137
97. Schluesener H.J., Lider O. Transforming growth factors beta 1 and beta 2: cytokines with identical immunosuppressive effects and a potential role in the regulation of autoimmune T cell function. J. Neuroimmunol. 24:1989;249
98. Johns L.D., Sriram S. Experimental allergic encephalomyelitis: neutralizing antibody to TGF beta 1 enhances the clinical severity of the disease. J. Neuroimmunol. 47:1993;1
99. Weiner H.L. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol. Rev. 182:2001;207
100. McCartney-Francis N.L., Frazier-Jessen M., Wahl S.M. TGF-beta: a balancing act. Int. Rev. Immunol. 16:1998;553
101. Calabresi P.A., Fields N.S., Maloni H.W., Hanham A., Carlino J., Moore J., et al. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology. 51:1998;289
102. Kohm A.P., Carpentier P.A., Anger H.A., Miller S.D. Cutting edge: CD4+CD25+regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169:2002;4712
103. Madakamutil L.T., Maricic I., Sercarz E., Kumar V. Regulatory T cells control autoimmunity in vivo by inducing apoptotic depletion of activated pathogenic lymphocytes. J. Immunol. 170:2003;2985
104. Shevach E., McHugh R., Piccirillo C., Thorton A. Control of T-cell activation by CD4+CD25+suppressor T cells. Immunol. Rev. 182:2001;58
105. Weiner H.L. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect. 3:2001;947
106. Falcone M., Sarvetnick N. Cytokines that regulate autoimmune responses. Curr. Opin. Immunol. 11:1999;670
107. Barrat F.J., Cua D.J., Boonstra A., Richards D.F., Crain C., Savelkoul H.F., et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 195:2002;603
108. Jahng A.W., Maricic I., Pedersen B., Burdin N., Naidenko O., Kronenberg M., et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194:2001;1789
109. Furlan R., Bergami A., Cantarella D., Brambilla E., Taniguchi M., Dellabona P., et al. Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur. J. Immunol. 33:2003;1830
110. Zhang J. T-cell vaccination for autoimmune diseases: immunologic lessons and clinical experience in multiple sclerosis. Expert Rev. Vaccines. 1:2002;285
111. Lider O., Reshef T., Beraud E., Ben-Nun A., Cohen I.R. Anti-idiotypic network induced by T cell vaccination against EAE. Science. 239:1989;181
112. Zhang J., Medaer R., Stinissen P., Hafler D., Raus J. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science. 261:1993;1451
113. Medaer R., Stinissen P., Truyen L., Raus J., Zhang J. Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet. 346:1995;807
114. Zhang J., Vandevyver C., Stinissen P., Raus J. In vivo clonotypic regulation of human myelin basic protein-reactive T cells by T cell vaccination. J. Immunol. 155:1995;5868
115. Van der Aa A., Hellings N., Medaer R., Gelin G., Palmers Y., Raus J., et al. T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study. Clin. Exp. Immunol. 131:2003;155
116. Gonzalez-Amaro R., Diaz-Gonzalez F., Sanchez-Madrid F. Adhesion molecules in inflammatory diseases. Drugs. 56:1998;977
117. Muraro P.A., Leist T., Bielekova B., McFarland H.F. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J. Neuroimmunol. 111:2000;186
118. Dedrick R.L., Bodary S., Garovoy M.R. Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection. Expert Opin. Biol. Ther. 3:2003;85
119. Baggiolini M. Chemokines and leukocyte traffic. Nature. 392:1998;565
120. Huang D., Han Y., Rani M.R., Glabinski A., Trebst C., Sorensen T., et al. Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation. Immunol. Rev. 177:2000;52
121. Ransohoff R.M. The chemokine system in neuroinflammation: an update. J. Infect. Dis. 186(Suppl. 2):2002;S152
122. Elices M.J. BX-471 Berlex. Curr. Opin. Investig. Drugs. 3:2002;865
123. Saeki T., Naya A. CCR1 chemokine receptor antagonist. Curr. Pharm. Des. 9:2003;1201
124. Gladue R.P., Tylaska L.A., Brissette W.H., Lira P.D., Kath J.C., Poss C.S., et al. CP-481,715: a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J. Biol. Chem. 278:2003;40473-40480
125. Wells T.N., Power C.A., Proudfoot A.E. Definition, function and pathophysiological significance of chemokine receptors. Trends Pharmacol. Sci. 19:1998;376
126. Sorensen T.L., Tani M., Jensen J., Pierce V., Lucchinetti C., Folcik V.A., et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103:1999;807
127. Sindern E., Patzold T., Ossege L.M., Gisevius A., Malin J.P. Expression of chemokine receptor CXCR3 on cerebrospinal fluid T-cells is related to active MRI lesion appearance in patients with relapsing-remitting multiple sclerosis. J. Neuroimmunol. 131:2002;186
128. Giunti D., Borsellino G., Benelli R., Marchese M., Capello E., Valle M.T., et al. Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. J. Leukoc. Biol. 73:2003;584
129. Columba-Cabezas S., Serafini B., Ambrosini E., Sanchez M., Penna G., Adorini L., et al. Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J. Neuroimmunol. 130:2002;10
130. Pluchino S., Quattrini A., Brambilla E., Gritti A., Salani G., Dina G., et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature. 422:2003;688